Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.


TSXV:VM - Post by User

Comment by WarrantOfficeron Apr 01, 2024 11:40am
123 Views
Post# 35962927

RE:RE:RE:RE:New Press Release - Voyageur Pharmaceuticals Files Audited Annual Financial Statements and Grants Stock Options

RE:RE:RE:RE:New Press Release - Voyageur Pharmaceuticals Files Audited Annual Financial Statements and Grants Stock OptionsPersonally, I do not trust current leadership, as they have consistently over stated and under performed. Management states they are entitled to 10% equity in this company on a yearly basis, IMO they are hugely over stating their personal worth. The 10% Equity Incentive Plan needs to be fully explained to share holders before the mext AGM. The next AGM must be zoomed and shareholders should, IMO be ready to replace leadership with a member / members of the SAB.  

We are expecting a 5 or 6 product line release 2nd quarter, which we are in now and yet not a word has been mentioned on any platform. For a company keen on hype, very little in this instance. Minimal interest in our company, proven by the slow share price deterioration since beginning of 2024.  IMO, time for a change. 
<< Previous
Bullboard Posts
Next >>